The author of this Viewpoint argues that there is currently insufficient evidence to guide the choice of therapy in rheumatoid arthritis, and highlights the need for large, simple, pragmatic trials designed to determine the best way to treat early or established rheumatoid arthritis, how aggressively to approach comorbidity, and how patients should be monitored.